Anzeige
Mehr »
Mittwoch, 18.06.2025 - Börsentäglich über 12.000 News
Entsteht hier die interessanteste spekulative Chance im kommenden Rohstoff-Boom?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QJV6 | ISIN: NL00150002Q7 | Ticker-Symbol: 05Y
Tradegate
18.06.25 | 19:57
1,500 Euro
-6,48 % -0,104
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
VIVORYON THERAPEUTICS NV Chart 1 Jahr
5-Tage-Chart
VIVORYON THERAPEUTICS NV 5-Tage-Chart
RealtimeGeldBriefZeit
1,4921,51019:59
1,4821,50019:58

Aktuelle News zur VIVORYON THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
12:39Vivoryon Therapeutics N.V.: Online-Präsentation für Investoren am 01.07.2025234Vivoryon ist ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das sich auf die Entwicklung innovativer, kleinmolekularer Arzneimittel zur Behandlung entzündlicher und fibrotischer...
► Artikel lesen
DiVivoryon Therapeutics N.V. Q1 2025 Financial Results and Operational Progress314Vivoryon Therapeutics N.V. Q1 2025 Financial Results and Operational Progress Continued progress in advancing varoglutamstat in kidney disease based on encouraging data and expansion of IP portfolioVaroglutamstat's...
► Artikel lesen
11.06.Vivoryon Therapeutics N.V. to Report Q1 2025 Financial Results and Operational Progress on June 17, 2025370Vivoryon Therapeutics N.V. to Report Q1 2025 Financial Results and Operational Progress on June 17, 2025 Halle To join the conference call via phone, participants may pre-register and will receive...
► Artikel lesen
06.06.Vivoryon Therapeutics N.V. Presents Meta-analysis Data of VIVIAD and VIVA-MIND studies at ERA 2025337Vivoryon Therapeutics N.V. Presents Meta-analysis Data of VIVIAD and VIVA-MIND studies at ERA 2025 Halle (Saale) / Munich, Germany, June 6, 2025 - Vivoryon Therapeutics N.V. (Euronext Amsterdam:...
► Artikel lesen
27.05.Vivoryon Therapeutics N.V. Expands Intellectual Property Portfolio with New U.S. Composition of Matter Patent Granted for Varoglutamstat383Vivoryon Therapeutics N.V. Expands Intellectual Property Portfolio with New U.S. Composition of Matter Patent Granted for Varoglutamstat Newly granted U.S. patent expected to provide exclusivity...
► Artikel lesen
13.05.Vivoryon Therapeutics N.V. to Hold its 2025 Annual General Meeting on June 24, 2025410Vivoryon Therapeutics N.V. to Hold its 2025 Annual General Meetingon June 24, 2025 Halle. ### About Vivoryon Therapeutics N.V.Vivoryon is a clinical stage biotechnology company focused on...
► Artikel lesen
VIVORYON THERAPEUTICS Aktie jetzt für 0€ handeln
29.04.Vivoryon Therapeutics N.V. Reports Full Year 2024 Financial Results and Provides Business Update583Vivoryon Therapeutics N.V. Reports Full Year 2024 Financial Results and Provides Business Update Successful strategic shift towards a focus on inflammatory and fibrotic diseases, in particular on...
► Artikel lesen
24.04.Vivoryon Therapeutics N.V. Signs Financing Agreement for up to EUR 15 Million431Vivoryon Therapeutics N.V. Signs Financing Agreementfor up to EUR 15 Million Halle (Saale) / Munich, Germany, April 24, 2025 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7)...
► Artikel lesen
17.04.Vivoryon Therapeutics N.V. to Report Full Year 2024 Financial Results and Operational Progress on April 29, 2025362Vivoryon Therapeutics N.V. to Report Full Year 2024 Financial Results and Operational Progress on April 29, 2025 Halle).Conference call detailsDate: April 29, 2025Time: 3:00 pm CEST / 9:00 am EDTThe...
► Artikel lesen
19.02.Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Update with KOL Speakers598Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Update with KOL Speakers Halle (Saale) / Munich, Germany, February 19, 2025 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7)...
► Artikel lesen
11.02.Vivoryon Therapeutics N.V. to Host Virtual R&D Update with KOL Speakers on February 18, 2025535Vivoryon Therapeutics N.V. to Host Virtual R&D Update with KOL Speakers on February 18, 2025 Halle (Saale) / Munich, Germany, February 11, 2025 - Vivoryon Therapeutics N.V. (Euronext Amsterdam:...
► Artikel lesen
14.01.Vivoryon Therapeutics N.V. Provides R&D-Update Further Strengthening Development Pipeline in Kidney Disease828Vivoryon Therapeutics N.V. Provides R&D-Update Further Strengthening Development Pipeline in Kidney Disease A meta-analysis of VIVIAD and VIVA-MIND1 data confirmed that treatment with varoglutamstat...
► Artikel lesen
10.12.24Vivoryon Therapeutics N.V. Reports Q3 2024 Results and Highlights Progress on Varoglutamstat in Kidney Disease959Vivoryon Therapeutics N.V. Reports Q3 2024 Results and Highlights Progress on Varoglutamstat in Kidney Disease Varoglutamstat Phase 2 program shows highly consistent, statistically significant and...
► Artikel lesen
09.12.24Vivoryon Therapeutics N.V. Presents Topline Phase 2 Data from VIVA-MIND Strongly Supporting Varoglutamstat's Potential to Improve Kidney Function918Vivoryon Therapeutics N.V. Presents Topline Phase 2 Data fromVIVA-MIND Strongly Supporting Varoglutamstat's Potential toImprove Kidney Function VIVA-MIND Phase 2 data confirm results of varoglutamstat's...
► Artikel lesen
04.12.24Vivoryon Therapeutics N.V. to Report Q3 2024 Financial Results and Operational Progress on December 10, 2024767Vivoryon Therapeutics N.V. to Report Q3 2024 Financial Results and Operational Progress on December 10, 2024 Halle (Saale) / Munich, Germany, December 04, 2024 - Vivoryon Therapeutics N.V....
► Artikel lesen
26.10.24Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of Varoglutamstat on Kidney Function at ASN Kidney Week 20241.322Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of Varoglutamstat on Kidney Function at ASN Kidney Week 2024 Selected for late-breaking oral presentation at ASN kidney week, the...
► Artikel lesen
11.10.24Vivoryon Therapeutics N.V. Announces Late-breaking Oral Presentation at the American Society of Nephrology Kidney Week 20241.048Halle (Saale) / Munich, Germany, October 11, 2024 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of...
► Artikel lesen
01.10.24Vivoryon Therapeutics N.V. Shares Highlights from Virtual Kidney Disease KOL Event964Halle (Saale) / Munich, Germany, October 1, 2024 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of...
► Artikel lesen
12.09.24Vivoryon Therapeutics N.V. Reports H1 2024 Progress Marked by Compelling Kidney Function Data and Execution of Strategy to Advance Varoglutamstat in Kidney Disease1.131Vivoryon Therapeutics N.V. Reports H1 2024 Progress Marked by Compelling Kidney Function Data and Execution of Strategy to Advance Varoglutamstat in Kidney Disease Primary focus is developing...
► Artikel lesen
05.09.24Vivoryon Therapeutics N.V. Announces Completion of Share Capital Reduction and Change to Articles of Association865Vivoryon Therapeutics N.V. Announces Completion of Share Capital Reduction and Change to Articles of Association Halle (Saale) / Munich, Germany, September 5, 2024 - Vivoryon Therapeutics N.V. (Euronext...
► Artikel lesen
Weiter >>
24 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,8